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The present study investigated the drug-carrier capacity of green activated carbon 
derived from fruit stones by steam-gas activation (ACSTA) towards the nonsteroidal an-
ti-inflammatory drug (NSAID) ibuprofen (IBU), and assessed the host-guest interactions 
and mass transfer mechanism/s of the drug microencapsulation and in vitro release pro-
cesses. The mass transfer studies outlined that the process of IBU encapsulation on ACSTA 
microparticles was predominantly controlled by intraparticle solid phase diffusion.
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Introduction
The development of innovative controlled-re-
lease (CRS) systems for biologically active sub-
stances, which are becoming increasingly widely 
used in medicine, pharmaceutics and agriculture, is 
one of the top priority areas of scientific research in 
the field of medical chemistry over the last decade.1
Microencapsulation of pharmaceutically active 
substances into appropriate carrier matrices ensures 
sustained or prolonged release of the drug; protec-
tion and stabilization of moisture-, photo- and oxi-
dation-sensitive biologically active compounds; 
prevention of incompatibility between drugs; pre-
dominant therapeutic action to specific activity 
sites.2 Adsorption as of drug molecules in porous 
micro-carrier particles is a readily adoptable micro-
encapsulation technique for thermo-, photoliable 
drugs, and such, with limited solubility. The micro-, 
meso-s and macro-porosity structure of the carriers 
is significant in providing sustained drug delivery.3
Drug delivery systems (DDS) are based on a 
variety of carriers, such as polymers, modified nat-
ural and synthetic mineral matrices, micro- and 
nanomaterials, etc., applied alone or in different 
combinations.3–5 The main qualitative indicators for 
assessing the effectiveness of CRS are the degree of 
incorporation and subsequent in vitro controlled 
 release of the biologically active substance, which 
depend on the physicochemical and mechanical 
properties of the composite, on the molecular char-
acteristics and properties of the organic substances, 
and on the interactions between the carrier and the 
incorporated substance.6
The efficiency of activated charcoal and its 
proven antitoxic activity due to its large specific 
surface area, high adsorption capacity and micropo-
rous structure provoked in vitro and in vivo studies 
on the potential of a variety of newly synthesized 
activated carbon based carriers as precursors for the 
development of effective DDS.7 Studies have been 
carried out on the adsorption of amino acids, vita-
mins, enzymes, and proteins on mesoporous carri-
ers based on silica and activated carbon. McCary 
and Rybolt investigated the incorporation of acet-
aminophen into various porous carbon-containing 
materials and subsequent release in phosphate buf-
fer medium at a temperature of 37 °C and pH 7.0.8 
Contemporary research has shown that, in agricul-
ture, newly developed controlled-release systems 
based on active carbon, unlike conventional forms, 
facilitate gradual and controlled release of pesti-
cides, reduce evaporation losses and minimize soil 
and water pollution caused by organic priority pol-
lutants.1,9
In vitro studies on adsorption of metoprolol, 
pindolol, salbutamol, furosemide and clonidine on 
activated carbon demonstrated that, although the 
drug affinity for the carrier is in good agreement 
with their hydrophobicity, the desorption rate is not 
proportional to their hydrophilicity, and was signifi-
cantly influenced by the particle size.10 Effective 
use of activated carbon as an oral adsorbent in the 
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primary treatment of acute theophylline poisoning 
has been investigated in vitro. The amount of the-
ophylline adsorbed by physiological saline was 
found to be greater than that of aqueous solution, 
and the increase in the contact area, by decreasing 
the particle size, increased the rate of adsorption.11 
The investigations of Tominaga et al. of a new 
treatment with activated charcoal swabs showed a 
remarkable improvement in the symptoms of bacte-
rial vaginosis when treated with activated charcoal 
swabs.12 This approach showed effective treatment 
of this infection without adverse side effects.
The comparative review and analysis of the re-
cently published scientific results proves the appli-
cability but also the existence of a number of disad-
vantages of universal and alternative activated 
carbons and mixtures of composites with carbon- 
containing materials as “carriers” of biologically 
active molecules, mainly in terms of controlling and 
achieving an optimal degree of desorption of the ac-
tive ingredient in real or simulated biological medi-
um.
Therefore, the outline of this new priority area 
in medical chemistry, and the lack of investigations 
on the applicability of innovative Bulgarian activat-
ed carbon derived from waste fruit stones as a car-
rier of biologically active substances, provoked the 
objectives of the current research. Detailed studies 
on the encapsulation of biologically active sub-
stances are significant and useful only if they in-
clude extensive study of the equilibrium, kinetics of 
encapsulation and release behavior, as well as the 
rate limiting mass transfer mechanism/s.13–15
The aim of the present study was to investigate 
the drug-carrier capacity of green activated carbon 
derived from fruit stones by steam-gas activation 
(ACSTA) towards the nonsteroidal anti-inflamma-
tory drug (NSAID) ibuprofen, and to assess the 
host-guest interactions and mass transfer mecha-




Ibuprofen (C13H18O2, CAS No. 15687-27-1, 
HPLC, 99.9 %), NaCl (p.a., > 99.5 %), NaOH (p.a. 
> 98 %) and HCl (reagent grade, 37 %) were sup-
plied by Sigma-Aldrich. The activated carbon de-
rived from fruit stones by steam-gas activation 
(ACSTA) was supplied by “GANDEV-ELI-ILIA 
GANDEV” ET, Kamenovo Village, Bulgaria. Its 
physicochemical characteristics are presented in 
 Table 1.
UV/Vis analyses
The drug concentrations in liquid and solid 
phase were determined by UV/VIS spectrophotom-
eter DR 5000 Hach Lange (Germany), supplied 
with 10 mm quartz cuvettes. The absorbance spec-
tra were measured at maximum wavelength λ = 263 
nm with 2 nm slit with 900 nm min–1 scan speed 
and very high smoothing. All UV/Vis analyses were 
made in triplicate.
Potentiometric titration, point of zero charge, 
and microscopic analyses
The determination of the acidic and basic ac-
tive sites and functional groups on the AB surface 
was performed by potentiometric titration of 1.000 
g of the solid phase with 0.1 M NaOH and 0.1 M 
HCl. The point of zero charge (pHPZC) of ACSTA 
was experimentally determined by the solid phase 
addition method.16 The microscopic morphological 
analyses of the activated carbon were performed 
with a broadband digital binocular optical micro-
scope 50–1000x (Biomed).
FTIR spectroscopy
FTIR spectra of ACSTA and ibuprofen-loaded 
ACSTA were determined on Bruker Tensor 37 FTIR 
spectrometer using KBr pellet technique. For each 
sample, 64 scans were collected at a resolution of 2 
cm–1 over the 4000–400 cm–1 wavenumber region.
Solid-state drug microencapsulation
Ibuprofen solid-state encapsulation on ACSTA 
microparticles was accomplished by the addition of 
0.050 g solid carrier to six IBU/EtOH solutions with 
initial concentrations in the range 25–200 µg mL–1 
and volume 20 mL each. The obtained experimental 
series was agitated for 100 h on IKA®KS 130 Basic 
Shaker at 560 rpm, pH 7.0, and temperature 25 oC. 
The solid dispersion systems were filter ed through 
0.45 µm sterile syringe filters (Sartorius Minisart®) 
Ta b l e  1  – Physicochemical characteristics of ACSTA
 Characteristic parameter Value
Fractional composition, µm 250–500
Absorption activity towards I2, mg g
–1 600
Absorption activity towards CH3COOH 580
Total ash, % 0.08
Specific surface area, m2 g–1 490
pH 6.5–7.5
Moisture, % 2.5
Bulk density, g dm–3 630
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and centrifuged at 8000xg on Heraeus Labofuge 
200 (Thermo, Electron Corpo ration) centrifuge. The 
NSAID concentrations in the supernatants were 
measured spectrophotometri cally. The encapsula-
tion efficiency of IBU into the ACSTA support was 
calculated by:
( )total amount of drug amount of free drug, %  ·100




The parameter drug loading capacity (DLC) 
expresses the amount of drug in the particles divid-
ed by the weight of the carrier system. DLC was 
calculated by:




The time dependence of the microencapsula-
tion process was investigated in a standard batch re-
actor with a Heidolph impeller. In 60-mL IBU/EtOH 
solution with initial concentration 100 µg mL–1 
were added 0.400 g ACSTA. The system was sub-
jected to constant mixing at 450 rpm, at T = 25 ºC 
for 180 min. Samples (3.5 mL) from the bulk sys-
tem, taken at definite time intervals, were filtered 
through 0.45 µm sterile syringe filters (Sartorius 
Minisart®) and centrifuged at 8000xg on Heraeus 
Labofuge 200 (Thermo, Electron Corporation) cen-
trifuge. The NSAID concentrations in the superna-
tants were measured spectrophotometrically.
In vitro release study
In vitro IBU release behavior in simulated bio-
logical medium was investigated by agitating 0.300 
g dried NSAID-loaded ACSTA composite samples 
dispersed in 20 mL simulated gastric fluid solution 
(without pepsin) – 0.2 % (w/v) NaCl in 0.7 % (v/v) 
HCl, at pH 1.2, and at constant temperature T = 
37±0.5 oC in a Digital Waterbath WNB 22 (Mem-
mert GmbH). The kinetics in vitro release experi-
ments were conducted in standard batch mode 
equipment consisting of a vessel (25 mL) and a 
Heidolph impeller at constant agitation rate 100 
rpm. With respect to the constructive dimensions, 
the following ratios and correlations are valid:
 z = D; b = 0.5·D; h = 1/3·z,
where z is the solution height (m); D – vessel diam-
eter (m); b – paddle blades height (m); h – distance 
between the vessel bottom and the paddle bottom 
(m).
At various time points, supernatants were iso-
lated by centrifugation, and 3.5 mL sample was tak-
en out instead of the same volume of fresh medium. 
The amount of released drug was analyzed spectro-
photometrically at 263 nm.
Interpretative modelling
The experimental equilibrium isotherms were 
described by five mathematical equilibrium models 
(Table 4). The kinetics experimental data of IBU 
microencapsulation on ACSTA particles was analy-
zed by assessment of the applicability of six kinet-
ics, mass transfer and diffusion mathematical mod-
els (Table 5). The mathematical models applied to 
the experimental data of IBU release from the ob-
tained drug-delivery composite are listed in Table 7.
Error functions analyses
The experimental data was analyzed by linear 
and non-linear regression analyses and determina-
tion of the corresponding correlation coefficients 
(R2) and SSE, MSE, RMSE and chi-square (χ2) er-
ror functions.
Results and discussion
UV/VIS absorption spectra of IBU
The absorption spectra of IBU in the UV re-
gion were registered at the specific wavelength λ = 
263 nm (Fig. 1a) for all tested drug initial concen-
trations and contained no additional interference 
peaks that could influence the analytical results. 
The standard plot of IBU characterized with high 
correlation coefficient (R2 = 0.995) (Fig. 1b).
Surface characterization of ACSTA
The importance of the surface characteristics of 
the carrier in driving and modulating the biochemi-
cal fate of organic molecules is now a solid and 
well-assessed key fact. The physicochemical prop-
erties of organic surfaces play a crucial role in de-
termining the interaction of a solid with bio-active 
organic molecules.17
Digital microscopy
The digital microscopic images of ACSTA at 
10x, 100x, 400x and 1000x magnification (Fig. 2) 
display the high porosity of the microparticles and 
the homogeneous nature of the solid surface.
Point of zero charge
Point of zero charge is of fundamental impor-
tance in surface science. In the field of drug-deliv-
ery systems design, it determines how easily a car-
rier is able to adsorb biologically active molecules. 
The pHPZC of ACSTA was determined to be 9.6. 
Consequently, at pH 7.0, i.e., below pHPZC, the acti-
vated carbon surface is positively charged.
(2)
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F i g .  1  – a) UV absorption spectra and b) calibration curve of ibuprofen
(a)
(b)
 100 µg mL –1   120 µg mL –1   140 µg mL –1   
 180 µg mL –1    200 µg mL –1  
Co mg mL–1
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Potentiometric titration
The experimental Boehm titration data of ACS-
TA (with 0.1 M NaOH and 0.1 M HCl) is presented 
as zero-, first-order potentiometric curves and re-
vised as Gran’s plots (Fig. 3). Gran´s method is 
based on the transformation of a titration curve into 
two linear functions vs. the volume of added titrant 
before and after the end-point titration.18,19 The in-
tersections of the linear portions with the volume 
axis correspond to the equivalence points V’ and 
V”.20 Based on these results, the density of the acid-
ic and basic sites on the carbon surface was calcu-
lated. The values of the strong, weak, very weak 
acidic sites, and total basic sites densities are pre-
sented in Table 2.
The basic surface sites of activated carbons are 
usually of Lewis type, associated with π elec-
tron-rich regions within the basal planes.21 Basicity 
of activated carbons can be associated with: (i) res-
onating-electrons of carbon aromatic rings that at-
tract protons, and (ii) basic surface functionalities 
(e.g., N-containing groups) that are capable of bind-
ing with protons. It was proposed that certain oxy-
gen containing surface functionalities, such as 
chromene, ketone, and pyrone, can contribute to the 
carbon basicity.22 The predominant acidic sites on 
biochar surfaces are mainly carboxylic, lactone, and 
phenolic groups.
FTIR analyses
The FT-IR spectra of IBU, ACSTA and 
IBU-loaded ACSTA (Fig. 4) were recorded to out-
line and analyze the possible interactions between 
IBU and the microparticles matrix. The conducted 
comparative detailed assessment of the characteris-
tic FTIR spectra displayed significant variations in 
the intensity of relevant bands, clearly indicating 
the existence of strong interactions between the 
drug and the excipient.
The FTIR data presented in Table 3 emphasize 
the influence of the encapsulated biologically active 
molecules on the spectral characteristics of the car-
rier. The increased intensities of IBU-ACSTA peaks 
at 2922 and 1392 cm–1 are attributed to significant 
CH2– and CH3-symmetric stretching vibrations 
within IBU molecules. The registered smooth peaks 
at 2738 and 2679 cm–1, assigning the presence of 
O-valence vibrations in the carboxylic OH-group, 
were solely due to the incorporated drug molecules. 
Strong CH3-asymmetric deformations and CH2-scis-
soring of IBU molecules are associated with the 
band at 1456 cm–1 on the drug-loaded carbon spec-
trum.
Probable interactions between the organic mol-
ecules and ACSTA particles, related to decreased 
CH–CO– and OH-in-plane deformations, resulted 
in reduced intensity of IBU spectral lines at 1420 
and 1321 cm–1, respectively. The latter assumption 
was supported by the observed increased intensity 
and area of IBU-ACSTA FTIR bands at 1508, 1541, 
1521, 1284, 1147, 1107, 1031, 626 and 420 cm–1 
attributed primarily to the aromatic ring C–H, 
C=C–C in-plane deformations and stretching vi-
brations of the drug molecules. Possible intermolec-
ular rotations of the ibuprofen molecules during 
their encapsulation within the solid matrix micro-
pores are the probable reason for the encountered 
F i g .  2  – Digital microscopic images of ACSTA (10x – 1000х)





Weak acidic sites, 
mmol g–1
Very weak acidic 
sites, mmol g–1
Total acidic sites, 
mmol g–1
Total basic sites, 
mmol g–1 pHPZC
ACSTA 2.55 0.60 1.87 5.02 6.55 9.6
    10×                                                       400×                                                            1000×
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F i g .  3  – Zero-order, first-order potentiometric curves and Grans plot of ACSTA
 Zero-order potentiometric curve  first-order potentiometric curve
    V′   V′′
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Ta b l e  3  – Characteristic FTIR vibrations and bends of IBU, ACSTA and IBU-loaded ACSTA23–25
Bend assignments
Wavenumber, cm–1
IBU IBU–loaded ACSTA ACSTA
OH-stretching – 3504, 3404, 3276 3444
CH asymmetric stretching 3094, 2958 – –
CH2-symmetric stretching








C≡C-stretching vibrations – 2351 2362, 2337, 2314
OH O-valence vibrations 2729 2630
2738* 
2679* –
C=O-stretching vibrations 1722 1716* –
C=O-stretching vibrations in aldehyde/keto/
carboxylic groups and quinones – 1697–1616 1700–1630





CH3-asymmetric deformations; CH2-scissoring 1462 1456
* 1452
CH–CO-deformations 1420 1417* 1421
CH3-symmetric stretching 1380 1392
* –
C=O/C–O-stretching in carboxylic groups – 1373–1361 1377–1363
OH-in-plane deformations 1321 1328* 1332
=C–H-in-plane deformations 1268 1284* –
C–C-stretching vibrations 1230 1245* –
C–O-stretching vibrations 1183 1184* –
=C–H-in-plane deformations 1122, 1067 1147*, 1107*, 1031* –
C–O-stretching vibrations 970 972* 974
C–H-out-of-plane vibrations 866 864* merged peaks
CH2-rocking vibrations 779 771
* 765
C–H-out-of-plane deformations 668 673* 670–676 merged peaks
C–H-in-plane ring deformations 636 626* 640
C–C deformations; CH2-in-plane rocking;  
CH2-/CH3-deformation vibrations
600–460 600–450 600–450
C=C–C-aromatic ring asymmetric bending; 





*FTIR vibrations attributed to IBU
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C–H–out-of-plane vibrations and deformations at 
864 and 673 cm–1 on the IBU-loaded carbon spec-
trum. The comparative analyses of the FT-IR spec-
tra of IBU, ACSTA and IBU-loaded ACSTA re-
vealed that, in the prepared NSAID/carbon carrier 
system, the strong bands assigned to the vibration 
of the drug molecules were predominant, which 
provided evidence for the high extent of IBU en-
capsulation in the carbon matrix.
Equilibrium study
Тo assess the versatility and tuneability of drug 
loading, investigations on the encapsulation behav-
ior of the biologically active molecules on the stud-
ied solid microcarrier at equilibrium conditions are 
essential. In the present study, the highest achieved 
ACSTA encapsulation efficiency towards IBU at 
equilibrium conditions was E = 52 %, and the max-
imum equilibrium capacity – qe
max = 19.5 µg IBU 
mg–1 ACSTA (Fig. 5a).
The experimental equilibrium data were de-
scribed by five mathematical models by non-linear 
regression analyses. The values of the calculated 
isotherm parameters and error functions are pre-
sented in Table 4. The comparative analyses of the 
mode of the experimental and model isotherms 
(Fig. 5b) supported by the highest R2 and the lowest 
SSE and chi-square (χ2) values determined that the 
four-parameter Baudu model presented the best de-
scription of the encapsulation behavior of the 
NSAID on the activated carbon. The adsorption iso-
therm had concave shape in the region of small 
equilibrium concentrations of IBU as a result of 
weak affinity of non-polar aromatic ring to polar 
OH-groups, but then followed a sharp increase of 
aromatic uptake. Obviously, it could be explained 
by the reorientation of the drug molecules owing to 
their increased concentration in the solution, thus it 
was easier for additional amounts to become fixed 
as a result of hydrophobic interaction.26 Baudu iso-
therm model has been developed mainly due to the 
rise of discrepancy in calculating Langmuir con-
stant and coefficient over a broad range of concen-
trations. Baudu isotherm model is the transformed 
form of the Langmuir isotherm. This model is only 
applicable in the range of (1+x+y) < 1 and (1+x) < 1. 
For lower surface coverage, Baudu model reduces 
to the Freundlich equation.
The monolayer sorption capacity (qB = 1.435 
mg g–1) predicted by Baudu model, was lower than 
the experimentally obtained. However, according to 
the plots in Fig. 5b, this model isotherm seemed to 
be the best-fitting model with regard to the experi-
mental equilibrium data. It displays the best repre-
sentation of the equilibrium behavior of the system 
in the low concentration range. At higher concentra-
tions, Baudu isotherm nearly coincides with the 
multilayer isotherm. However, due to the increased 
number of isotherm parameters in the four-parame-
ter Baudu model, it simulates the model variations 
more accurately. In the case of sorptive processes of 
organic macromolecules like drugs having different 
types of functional groups, the factors affecting 
sorption are large. Therefore, in the absence of a 
theoretical model that could account for the chemi-
F i g .  4  – FTIR spectra of fresh and IBU-loaded ACSTA
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F i g .  5  – a) Equilibrium drug concentration, encapsulation capacity, and efficiency for the system IBU/ACSTA; b) Experimental and 
model isotherms of the system IBU/ACSTA
(b)
(a)
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cal heterogeneity of the surface, and simultaneous 
prevalence of different sorption mechanisms, iso-
therm models having a greater number of model 
constants are able to predict the system behavior 
better.
Kinetics of IBU encapsulation
Drug release and its relationship with the kinet-
ics parameters of drug sorption onto ACSTA micro-
particles have been studied using IBU as a model 
drug. The sorption method is more flexible and can 
avoid limitations or problems which occur with 
molten or dissolution methods. To understand drug 
release sorption loading, kinetics and apparent mass 
transfer parameters, such as mass-transfer and dif-
fusion coefficients have been investigated. In this 
respect, six diffusion and kinetics models were ap-
plied to describe the experimental data. Their appli-
cability was ranked on the bases of the calculated 
regression coefficients and error functions by the 
linear/non-linear approach. According to the exper-
imental kinetics curve, equilibrium between the in-
corporated and released drug molecules was reached 
after 200 min.
The values of the calculated model parameters 
and error functions are presented in Table 5. Ac-
cording to the analyses of these data and the com-
parison of the modes of the experimental and model 
kinetics curves, it was established that the pseudo- 
first order, the mixed pseudo first-second order, and 
the intraparticle diffusion models characterized with 
the lowest applicability.
Ta b l e  4  – Values of the equilibrium model parameters and error functions16,27,28

















= +   (4)
qm = 25.551
KL = 0.383
aL = 0.015 
R2   0.945
SSE  14.651
MSE   2.930
RMSE   1.712
χ2   1.2582
Freundlich
Fn
e F eq K c= ⋅  (5)
KF = 1.435
nF = 0.511
R2   0.908
SSE  12.922
MSE   3.230
RMSE   1.797



















χ2   1.0774
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Second-order polynomial form:
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R2   0.913
SSE  23.930
MSE   5.983
RMSE  2.446





















R2   0.953
SSE  12.922
MSE   4.307
RMSE   2.075
χ2  0.9863
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Ta b l e  5  – Values of the kinetics/diffusion models parameters and error functions30–34 
Kinetics model Kinetics parameters Error functions
Pseudo-first order model
Non-linear form
( )1·t e t
dq k q q
dt
= −   (10)
Linear expression
( ) 1log log ·
2.303e t e








( )22·t e t
dq k q q
dt




1 1 1 ·
·t e e
t
q k q q
= +   (13)
k2 = 0.0027
qe2 = 19.885
























































( )exp  t
dq q
dt
α β= ⋅ − ⋅  (18)
Linear expression
( ) ( )1 1ln ln  tq tα ββ β= ⋅ ⋅ + ⋅  (19)
α = 6.720 µg mg–1 min–1

























Mixed surface reaction and diffusion controlled kinetics model k = 6.803·10–5 mL µg–1 min–1





where: k1 – rate constant of first order kinetics; qe1 – sorption capacity of first order kinetics, µg mg
–1; k2 – rate constant of second order 
kinetics; qe2 – sorption capacity of second order kinetics, µg mg
–1; ki – rate constant for intraparticle diffusion; I – model constant in 
the intraparticle diffusion model; α – initial sorption rate in Elovich model; β – desorption constant in Elovich model; k – rate 
coefficient mL µg–1 min–1; τ – coefficient related to diffusion; ueq – relative equilibrium uptake; α – initial sorption rate, µg mg
–1 
min–1; β – desorption constant related to surface coverage and activation energy for chemisorption, mg µg–1.
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F i g .  6  – Linear form of a) pseudo-second order, b) Elovich kinetics models, and c) mixed surface  
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The experimentally demonstrated observation 
of the sorption rate slowing down with time is ex-
plained by the Elovich model according to which, at 
first, the lower energy surface sites of the carbon 
saturate, and then the adsorption, shifts to the high-
er energy surface sites, resulting in a decrease in the 
sorption rate. The Elovich equation is known to de-
scribe chemisorption well, similarly to the assump-
tions of the pseudo-second order model, although 
the initial sorption rate predicted by the Elovich 
equation (α = 6.720 µg mg–1 min–1) is approximate-
ly 6 times greater than that determined by the pseu-
do-second order one (h = 1.068 µg mg–1 min–1). Be-
sides, the Elovich model accounts for the role of 
desorption expressed by the desorption constant (β 
= 0.321 mg µg–1) related to surface coverage and 
activation energy for chemisorption (Table 5). Both 
kinetics models characterized with significantly 
high values of the correlation coefficient (Fig. 6a, b; 
Table 5). The Elovich model is physically unsound 
as it predicts infinite sorption capacity at long peri-
ods of time. Therefore, it is suitable for kinetics far 
from equilibrium where desorption does not occur 
because of low surface coverage.29 The mixed sur-
face reaction and diffusion controlled kinetics mod-
el considers both diffusion and surface reaction as 
the rate-controlling steps. The significant effect of 
diffusion on the overall sorption process is deter-
mined by the value of the parameter τ (Table 5). To 
derive the equation that best fits the experimental 
data, an iteration procedure with 0 ≤ τ ≤ 100 was 
conducted. The model curves presented in Fig. 6c, 
the values of the calculated model parameters and 
error functions (Table 5) proved that the experimen-
tal kinetics behavior of the studied drug/carrier sys-
tem was best described at τ = 58 min. Consequently, 
it could be considered that IBU molecules diffuse 
toward ACSTA active sites and then, after 58 min 
contact time, they adsorb on the surface sites 
through a surface reaction mechanism.
Mass transfer mechanism of IBU encapsulation
The effect of the mass transfer mechanisms 
through the boundary layer fluid-solid phase and 
the diffusion of IBU molecules during the drug en-
capsulation on ACSTA microparticles were assessed 
by determination of the values of the characteristic 
mass transfer and diffusion parameters. The exter-
nal mass transfer coefficient, kf, calculated by McK-
ay and Weber-Mathews equations, characterized 
with significantly higher value as compared to the 
partial solid-phase mass transfer coefficient, ks 
 (Table 6). The latter indicates that the resistance 
which the solid phase renders to the drug molecules, 
significantly overlaps the boundary layer resistance. 
The mass transfer resistances were also analyzed by 
estimating the Biot number – Eq. (21), which is a 
dimensionless criterion for the predominance of ex-









The determination of the effective diffusivity 
coefficient, De, in Eq. (28) (Table 6) requires the 
calculation of the values of the solid phase diffu-
sion, Ds, and pore diffusion, Dp, coefficients (Table 
6). The value estimated in the present study of 
De = 5.744·10
–12 m2 s–1 for IBU is approximately 10 
times greater than the values of this coefficient for 
acetaminophen, diclofenac and sulfamethoxazole 
De = 2.63–9.33·10
–13 m2 s–1.34
It is accepted that, for Bi numbers < 0.5, the 
sorption process is limited by external mass trans-
fer. As the value of Bi obtained in the present study 
was above 100, it could be concluded that the pro-
cess of IBU encapsulation on ACSTA microparti-
cles was controlled predominantly by intraparticle 
solid phase diffusion.
In vitro release study
The use of in vitro drug dissolution data to 
 predict in vivo bioavailability of pharmaceutical 
formulations can be considered as the rational de-
velopment of controlled release systems. Model-de-
pendent methods are based on various assumptions 
and imply mathematical functions, which describe 
the dissolution profile. Once a suitable function had 
been selected, the dissolution profiles were evaluat-
ed depending on the derived model parameters.
Pepsin-free simulated gastric fluid was used for 
the in vitro release study, as the main aim of the 
research was to assess the encapsulation and release 
efficiency of ACSTA towards IBU. In this respect, 
the addition of an enzyme would cause degradation 
of the drug and lead to the release of its metabolic 
products, which would affect the required results.
According to the experimental data, the highest 
extent of IBU release from ACSTA microparticles in 
simulated gastric fluid solution was 134.31 µg mL–1, 
which was equal to desorption efficiency Edes 54.1 % 
at 298 K achieved after 1200 min. The experimen-
tally determined IBU concentration in the ACSTA 
matrix before its release was 117.1 mg g–1.
To outline the suitable release kinetics model 
describing the dissolution profile of IBU, nonlinear 
regression was applied. The experimental results 
from the in vitro desorption studies in simulated 
gastric fluid (pH = 1.2) were modelled by the Higu-
chi, Korsmeyer-Peppas, Weibull, and Peppas-Sahlin 
models. The values of the model parameters and er-
ror functions are presented in Table 7.
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Ta b l e  6  – Values of the mass transfer and diffusion coefficients of IBU encapsulation
Parameter Value Equation
Particle porosity, εp, – 0.34
Particle density, ρp, g cm
–3 576
Particle surface area, Ss, m
2 2.1·10–7
Microcarrier concentration, ms, g dm
–3 6.67
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Ibuprofen molecular volume, υA, Å
3 198.96
Ethanol molecular volume, υA, Å
3 48.45
Wilke-Chang coefficient for EtOH, B 2.00
Effective diffusivity coefficient, De, m
2 s–1 5.744·10–12 Crank equation:
























=   (31)
where ρp is particle density, g cm
–3; εp – particle porosity, –; К – linear isotherm slope, dm
3 g–1; τp – pore tortuosity factor (τp = 2 – 6); 
Dm – Wilke-Chang equation; μв – viscosity of water, Pa s; υА – molecular volume of the drug in Wilke-Chang equation, cm
2 g–1 mol–1; 
υB – molecular volume of EtOH in Wilke-Chang equation, cm
2 g–1 mol–1; MA – molecular weight of IBU, g mol
–1; MB – molecular 
weight of EtOH, g mol–1; A – coefficient characterizing the solute (A = 1.0 for non-associated liquids); B – coefficient characterizing 
the solvent (B = 4.3 for water).
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The Higuchi model gave no significant correla-
tion towards the experimental data, which was con-
sistent with the low R2 and high SSE, MSE and 
RMSE values determined by non-linear regression 
analyses (Table 7).
According to Table 7, the Peppas-Sahlin model 
characterized with better applicability as compared 
to the Higuchi model. The first term of the model 
considers the contribution of Fickian diffusion, 
while the second – case II relaxation. The exponen-
tial coefficient m relates to the purely Fickian diffu-
sion exponent. The ratio of relaxational (R) over 








= ⋅  (38)
The plot of R/F vs. t is presented in Fig. 7. Ac-
cording to the model assumptions, when R/F = 1, 
the release mechanism contains both erosion and 
diffusion equally; at R/F > 1 the relaxation (ero-
sion) dominates, while for R/F < 1, the rate-limiting 
role of Fickian diffusion dominates.
The Weibull model characterized with relative-
ly high value of the regression coefficient and ac-
ceptably low values of the other three error func-
tions, which proved its applicability towards the 
experimental data. The Weibull function predicts a 
general trend for free diffusion at short times tend-
ing toward fractal space, i.e., geometry controlled, 
diffusion with increasing time. The shape parame-
ter, b, characterizes the curve as either exponential 
(b = 1), S-shaped with upward curvature followed 
by a turning point (b > 1), or as one with a steeper 
initial slope than was consistent with the exponen-
tial (b < 1). The experimental data of IBU release 
from ACSTA microparticles were best fitted by the 
model at b = 1 (Fig. 8a). The time parameter, t rep-
resents the time interval necessary for 63.2 % drug 
release. According to the modes of the experimental 
and Weibull release kinetics curves in Fig. 8a, obvi-
ously the model characterizes with higher extent of 
applicability in the initial stages of the release pro-
cess.
Ta b l e  7  – Release models parameters and error functions
Model Parameters Error functions
Zero-order model
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at Ct /C0 < 0.6  at Ct /C0 > 0.6
kKP = 0.002  kKP = 0.224
n = 1.235  n = 0.211
at Ct /C0 < 0.6  at Ct /C0 > 0.6
R2 0.999   R2 0.999
SSE 1.39·10–4  SSE 5.98·10–5
MSE 1.39·10–4  MSE 2.99·10–5














at b = 1.0  at b = 0.2
C0
mod = 124.10  C0
mod = 56.68
a = 125   a = 3.289
t = 7.802  t = 15
at b = 1.0  at b = 0.2
R2 0.967   R2 0.901
SSE 0.038  SSE 0.119
MSE 0.008  MSE 0.024





· ·m mt PS PS
C k t k t
C
= +  (30)
k1PS  = 0.0769
k2PS  = 2.709·10
–5





Ct – cumulative amount of drug released in time t; C0 – initial amount of drug in solution (usually C0 = 0); k0 – zero-order release 
constant; D – diffusion coefficient of the drug molecule in the solvent in Higuchi model; ε – porosity of the matrix; S – surface area; 
KH – release rate constant in the Higuchi model; kKP – release constant incorporating structural and geometric dosage from characteristics 
in Korsmeyer-Peppas model; n – the release exponent indicating the drug release mechanism in Korsmeyer-Peppas model; a – time 
process parameter in Weibull model; t – lag time (in most cases zero); b – shape parameter in Weibull model: characterizes the curve 
as exponential (b = 1), S-shaped with upward curve followed by turning point (b > 1), or parabolic with higher initial slope, after that 
consistent with the exponential (b < 1); k1PS and k2PS – kinetics coefficients in Peppas-Sahlin model; m – diffusional exponent in 
Peppas-Sahlin model.
264 Z. Lyubenova Yaneva, Nonsteroidal Anti-Inflammatory Drug Solid-State…, Chem. Biochem. Eng. Q., 33 (2) 249–269 (2019)
F i g .  7  – Relaxation contribution (R)/Fickian diffusion contribution (F) ratio with respect to time
According to the values of the correlation coef-
ficients and error functions, the Korsmeyer-Peppas 
model displayed the best applicability towards the 
experimental release results (Table 7, Fig. 8b). The 
semi-empirical model of Korsmeyer-Peppas is ap-
plied for analyses of the release of pharmaceutical 
cylindrical shaped dosage forms, when the release 
mechanism is not well known or when more than 
one type of release could be involved. The value of 
the parameter n in the equation is indicative of the 
diffusion mechanism: for 0.45/0.5 ≤ n corresponds 
to a Fickian diffusion mechanism, 0.45/0.5 < n < 
0.89 to non-Fickian transport, n = 0.89 to relax-
ational transport, and n > 0.89 to super case II trans-
port. The applicability of the model to the experi-
mental data at different values of n was evaluated in 
the entire concentration range 0 < Ct /C0 < 1 (Fig. 
8b). The analyses of the results outlined that the ex-
perimental data could not be significantly correlated 
with a single n value for the entire concentration 
interval, which in turn is indicative of the presence 
of more than one release mechanism. A boundary 
value of Ct /C0 ~ 0.6 distinguishing the probable 
rate-controlling mechanisms in the initial and later 
stages of the release process was defined. The value 
of n determined at Ct /C0 < 0.6 in the current study 
was n = 1.235, which demonstrated the complex in-
fluence of probable abrasion of the solid microcar-
rier due to mechanical scraping of the surface by 
friction between the moving particles and diffusion 
on the release of the organic substance during the 
initial stages of the process. At Ct /C0 > 0.6, the val-
ue of n was 0.211, which proved undoubtedly the 
limiting role of Fickian diffusion mechanism during 
the later stages of the process.
Host-guest interactions
The presence of inter- and intramolecular 
non-covalent interactions and bonded structures be-
tween drugs and carrier-matrices are identified as a 
key factor affecting drug encapsulation and re-
lease.37 In addition, numerous factors, such as drug–
carrier interaction, morphology of the matrix, po-
rosity, and carrier concentration can influence the 
complex processes of the encapsulation and release 
profile of drugs.
Ibuprofen characterizes as a weak acid (pKa = 
4.91) with poor solubility in water and very good 
solubility in ethanol and methanol. Its physico-
chemical and molecular characteristics are present-
ed in Table 8. The molecule contains an asymmetric 
C-atom in the propionic acid residue, which deter-
mines the presence of two enantiomers: the S-enan-
tiomer having analgesic and anti-inflammatory ac-
tivity, and the R-isomer, which is inert. As a result 
of molecular modeling, IBU molecule was charac-
terized by the following dimensions: 1.03 nm 
(length), 0.52 nm (width), 0.43 nm (thickness).38
Ta b l e  8  – Physicochemical and molecular properties of IBU
Chemical formula C13H18O2
Molecular mass 206.29 g mol–1
Density 1.03 g cm–3
Melting temperature 75 to 78 °C 
Boiling temperature 157 °C 
Solubility in water 0.021 mg mL–1 (20 °C)
Dissociation constant Ka = 1.2 · 10
–5 (25 °C)
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F i g .  8  – Fit of drug dissolution data with: a) Weibull release model, and b) Korsmeyer-Peppas release model
(a)
(b)
  exp. data   n = 0.1   n = 0.15 
  n = 0.18   n = 0.2   n = 0.23  
  n = 0.25   n = 0.34   n = 0.35  
  n = 0.36   n = 0.38   n = 0.4 
 n = 0.5   n = 0.55   n = 0.6 
  n = 0.7  n = 0.8  
  n = 1.235 at Ct/C0 < 0.6; n = 0.211 at Ct/C0 > 0.6)
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 The organic molecule contains a polar carbox-
ylic group (–COOH), but the available non-polar 
alkyl groups and the benzene ring significantly re-
duce the polarity of the organic molecule. The com-
parative analysis of the physicochemical, spectral 
characteristics of the organic molecule, the surface 
properties of the microcarrier, as well as the kinetic 
encapsulation and release of the biologically active 
substance led to the conclusion that the interaction 
between IBU molecules and ACSTA microparticles 
was due to electrostatic and dispersion intermolecu-
lar forces, as well as formation of H-bonds. Al-
though the hydrogen bond is a weak interaction, 
Hao and Li found that a substantially high number 
of hydrogen bond formations could decrease drug 
release rate.39,40 The major active moieties of ACS-
TA microparticles are –OH and –COOH surface 
groups that interact with polar molecules and vari-
ous functional groups in the structure of the organic 
molecules. The surface electrically charged groups 
of the carrier are: –OH2
+ at pH < pHPZC; –O- at pH > 
pHPZC, and electroneutral –OH at pH ≈ pHPZC. In al-
kaline medium repulsion forces between the surface 
OH– of ACSTA and the anionic –COOH groups of 
O would act, but since IBU molecules are predomi-
nantly non-dissociated in EtOH solution, the effect 
of these interactions in the system under examina-
tion is insignificant. According to Pawlish et al., the 
use of π-π stacking, although with relatively low 
strength, can still improve the encapsulation proper-
ties and stability of the carriers towards loading of 
drugs containing aromatics.37 In the present study, 
the high degree of encapsulation of IBU on AB mi-
croparticles is indicative of dominant hydrophobic 
interactions: π-π interactions due to dispersion at-
traction between π-orbitals in the phenyl groups in 
the ACSTA layers and π-electrons in the aromatic 
ring of the organic molecule. However, the role of 
the forming intermolecular H-bonds between the 
O-containing functional groups of ACSTA and the 
H-atoms of the –COOH group and the alkyl resi-
dues in the IBU molecule is significant. The inter-
actions discussed are schematically represented in 
Fig. 9.
The conclusions drawn in the present study 
correspond to the observations of other scientists in-
vestigating the role of various non-covalent interac-
tions working in tandem to provide multiple non-co-
valent intermolecular forces between drugs and 
carriers in view of the adsorption of non-steroidal 
anti-inflammatory pharmaceuticals on different 
types of activated carbons and subsequent in vitro 
release of the target compounds.37,40–43
Besides, IBU belongs to the BCS class II drugs, 
which characterize with low solubility, high perme-
ability, and bioavailability limited by their solvation 
rate. Thus, the establishment of a correlation be-
tween the fundamental parameters: in vivo bioavail-
ability and the in vitro solvation of IBU, is essential 
IBU dissociation in aqueous solution proceeds as follows:
F i g .  9  – Physicochemical interaction between ACSTA surface functional groups and IBU molecules
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for defining the oral drug absorption in humans, 
their pharmacokinetics, pharmacodynamics path-
ways in the body, and the therapeutic efficiency of 
newly designed drug-carrier microformulations.41,44
Conclusions
The FTIR analyses provided evidence of the 
high extent of IBU encapsulation in the prepared 
NSAID/carbon carrier system, as the strong bands 
assigned to the vibration of the drug molecules were 
predominant. The highest achieved ACSTA encap-
sulation efficiency towards IBU at equilibrium con-
ditions was E = 52 %, and the maximum equilibri-
um capacity qe
max = 19.5 µg IBU mg–1 ACSTA. The 
four-parameter Baudu model presented the best de-
scription of the encapsulation behavior of the 
NSAID on the activated carbon. The significant 
consistency of the mixed surface reaction and diffu-
sion controlled kinetics model outlined the rate-lim-
iting role of diffusion during the initial 58 min of 
the drug microencapsulation, followed by adsorp-
tion of the biologically active molecules on the ac-
tive sites through a surface reaction mechanism. 
The value of Biot number Bi > 100 defined the pro-
cess of IBU encapsulation on ACSTA microparti-
cles as controlled predominantly by intraparticle 
solid phase diffusion. The significant applicability 
of the semi-empirical Korsmeyer-Peppas model 
demonstrates the complex influence of probable 
abrasion of the solid microcarrier due to mechanical 
scraping of the surface and diffusion on the in vitro 
IBU release of IBU during the initial stages com-
bined with the limiting role of Fickian diffusion 
mechanism during the later stages of the release 
process. The predominant host-guest interactions 
between IBU molecules and the carrier include hy-
drophobic π-π interactions and intermolecular 
H-bonds between ACSTA O-containing functional 
groups and the H-carboxylic atoms and alkyl resi-
dues in the IBU molecule. The applicability of AC-
STA microparticles as appropriate NSAID carriers 
in pharmacy and medicine was proven by the mini-
mum ash content of the matrix, as well as the 
achieved prolonged and efficient in vitro drug re-
lease, consistent with the single dosage prescrip-
tions and recommended dosage allowances for hu-
mans. To study in details the probable variations of 
the newly designed drug-carrier system behavior in 
real biological environment, future microbiological 
and clinical experiments shall be conducted.
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